Poor achievement of lipid targets after acute coronary syndrome: what can we improve?

Sher May Ng, Jiliu Pan and Ajay K Gupta
Med J Aust 2022; 216 (9): . || doi: 10.5694/mja2.51507
Published online: 16 May 2022

Overcoming problems that impede the delivery of evidence‐based care is needed to bridge gaps between science and improving health

The benefits of lipid‐lowering therapy for the secondary prevention of atherosclerotic cardiovascular disease, including its effect on mortality, have been recognised since the publication of the seminal 4S trial in 1994.1 Recent clinical trials of novel lipid‐lowering therapies in people taking statins have found that the lower the low‐density lipoprotein cholesterol (LDL‐C) level achieved, the lower the risk of adverse cardiovascular events.2 It is beyond doubt that people at high risk of adverse cardiovascular events, including those with a history of acute coronary syndrome, benefit most from aggressive lipid‐lowering therapy. Accordingly, the recommended LDL‐C targets are lowest for such people, and have been continually reduced in international guidelines over time.3

  • Sher May Ng1
  • Jiliu Pan2
  • Ajay K Gupta3

  • 1 Barts Health NHS Trust, London, United Kingdom
  • 2 Harefield Hospital, Harefield, United Kingdom
  • 3 Centre for Clinical Pharmacology, Queen Mary University of London, London, United Kingdom


Competing interests:

No relevant disclosures.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.